GlassScriptPhysician profile
Charles Kovaleski
NPI 1811972391
$9,375.16
in general payments reported to CMS, 2019-2025
35 companies · $877 in 2025
The $877 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,129 · 2020: $932 · 2021: $1,379 · 2022: $1,902 · 2023: $1,513 · 2024: $1,644 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,033.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,686.78 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $987.52 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $734.38 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $663.39 | 2019-2025 | |
| Ucb, INC. | $522.94 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $475.12 | 2019-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $466.85 | 2020-2025 | Tremfya, Simponi Aria, Stelara |
| Sun Pharmaceutical Industries INC. | $413.43 | 2019-2025 | Blu-U |
| Lilly USA, LLC | $338.74 | 2019-2024 | Taltz, Ebglyss |
| Pfizer INC. | $298.71 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $284.29 | 2022-2025 | Sotyktu |
| Organogenesis INC. | $276.74 | 2021-2025 | Cygnus Dual, Affinity, Via Matrix |
| Leo Pharma INC. | $211.83 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $152.89 | 2019-2025 | Nemluvio |
| Biofrontera INC. | $119.46 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.52 | 2022-2025 | Spevigo |
| Incyte Corporation | $88.70 | 2021-2024 | Opzelura |
| Dusa Pharmaceuticals, INC. | $78.64 | 2019 | |
| Genentech USA, INC. | $60.75 | 2019-2023 | Erivedge |
| Helsinn Therapeutics (U.S.), INC. | $58.66 | 2020-2021 | |
| Convatec INC. | $51.35 | 2023 | |
| Kyowa Kirin, INC. | $44.05 | 2020-2021 | |
| Celgene Corporation | $37.70 | 2019 | |
| Fresenius Kabi USA, LLC | $35.76 | 2024 | Idacio |
| Arcutis Biotherapeutics, INC. | $33.20 | 2023-2024 | Zoryve |
| Allergan, INC. | $21.58 | 2022 | |
| Paratek Pharmaceuticals, INC. | $21.42 | 2022 | |
| Almirall LLC | $18.69 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.98 | 2021 | |
| Journey Medical Corporation | $15.84 | 2023 | |
| Krystal Biotech INC | $14.23 | 2024 | Vyjuvek |
| Merck Sharp & Dohme LLC | $13.99 | 2019 | |
| Strata Skin Sciences, INC. | $12.95 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.56 | 2021 | |
| Kerecis Limited | $8.52 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Kovaleski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.